-
Article
Open AccessTumour-infiltrating CD68+ and CD57+ cells predict patient outcome in stage II–III colorectal cancer
The aim of our study was to evaluate the prognostic role of immunological microenvironnement in stage II–III CRC patients.
-
Article
Open AccessQuality-of-life findings from a randomised phase-III study of XELOX vs FOLFOX-6 in metastatic colorectal cancer
A phase-III trial showed the non-inferiority of oral capecitabine plus oxaliplatin (XELOX) vs 5-fluorouracil/leucovorin plus oxaliplatin (FOLFOX-6) in terms of efficacy in first-line treatment of metastatic color...
-
Article
Open AccessPhase I trial of oxaliplatin with fluorouracil, folinic acid and concurrent radiotherapy for oesophageal cancer
This dose escalation study was designed to determine the maximum tolerated dose (MTD) and recommended doses (RDs) of 5-fluorouracil (5FU), folinic acid and oxaliplatin (FOLFOX) with concomitant radiotherapy in...
-
Article
Open AccessMulticentre phase II trial of capecitabine plus oxaliplatin (XELOX) in patients with advanced hepatocellular carcinoma: FFCD 03-03 trial
Evaluation of new drug combinations is needed to improve patients' prognosis in advanced hepatocellular carcinoma (HCC). The purpose of this study was to evaluate the safety and efficacy of the capecitabine–ox...
-
Article
Open AccessIrinotecan is active in chemonaive patients with metastatic gastric cancer: a phase II multicentric trial
To assess the response rate and the tolerance of irinotecan as first-line therapy, 40 patients with metastatic gastric cancer received irinotecan 350 mg m−2 every 3 weeks administered as a 30 min infusion. Among ...
-
Article
Open AccessFactors predicting efficacy of oxaliplatin in combination with 5-fluorouracil (5-FU) ± folinic acid in a compassionate-use cohort of 481 5-FU-resistant advanced colorectal cancer patients
A statistical analysis was performed on the patient data collected from two compassionate-use programmes using oxaliplatin (Eloxatin®) + 5-fluorouracil (5-FU) ± folinic acid (FA), to identify predictive factor...
-
Article
Open AccessCancer of the rectum
-
Article
Open AccessTreatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin
The purpose of this study was to evaluate by a retrospective analysis of 53 patients the efficacy of chemotherapy combining etoposide and cisplatin in the treatment of neuroendocrine tumours. The regimen was a...